The Trump administration promises ‘greater transparency’ in drug price negotiations

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug price negotiations under President Donald Trump’s administration. The statement follows criticism from the pharmaceutical industry regarding the program.

Read more…

​The U.S. Centers for Medicare and Medicaid Services (CMS) said on Wednesday that it would seek “greater transparency” in drug price negotiations under President Donald Trump’s administration. The statement follows criticism from the pharmaceutical industry regarding the program.Read more… 

Leave a Reply

Your email address will not be published. Required fields are marked *